Plasma metabolomic characteristics of atrial fibrillation patients with spontaneous echo contrast
Related Experiment Video
Updated: Jun 7, 2025
Estimating Bilateral Atrial Function by Cardiovascular Magnetic Resonance Feature Tracking in Patients with Paroxysmal Atrial Fibrillation
Published on: July 20, 2022
Bingshuo Shi1, Rong Suo1,2, Wenhua Song1
1Tianjin Key laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, The Second Hospital of Tianjin Medical University, No. 23 Pingjiang Road, Hexi District, Tianjin, 300211, China.
Insights
Spontaneous echo contrast (SEC) in atrial fibrillation (AF) patients is linked to distinct plasma metabolic patterns. Identifying these metabolic differences can aid in preventing thrombus formation in AF.
Area of Science:
- Cardiology
- Metabolomics
- Biochemistry
Background:
- Spontaneous echo contrast (SEC) in atrial fibrillation (AF) patients signifies a prethrombotic state.
- Understanding plasma metabolomics is crucial for preventing thrombus formation in AF, especially early on.
Purpose of the Study:
- To investigate metabolic pathways associated with SEC in AF patients.
- To identify differential metabolites influencing thrombotic states.
Main Methods:
- Non-targeted metabolomics analysis of plasma from AF patients categorized into non-SEC, low-SEC, and high-SEC groups.
- Data quality control, differential metabolite analysis, component analysis, and KEGG cluster analysis were performed.
Main Results:
- A clear differential metabolic pattern was observed between SEC and non-SEC groups.
- 35 and 142 significantly differential metabolites were identified in venous and atrial plasma, respectively.
- Metabolic dysregulation in atrial plasma was more severe than in venous plasma.
Conclusions:
- SEC in AF patients is associated with significantly different metabolic patterns.
- The study enhances understanding of SEC and thrombosis mechanisms in AF.
- Findings support targeted metabolite screening for therapeutic intervention and provide dietary recommendations for AF patients with SEC.
Background:
The spontaneous echo contrast (SEC) in patients with atrial fibrillation (AF) indicates a prethrombic state that ultimately progresses into thrombus formation. A comprehensive understanding of specific plasma metabolomics characteristics may protect AF patients from thrombus, particularly in the early stage.
Objectives:
Through the investigation of metabolic pathways, we endeavor to uncover the metabolomic characteristics associated with SEC states, and to examine the differential metabolites by which may exert their influence on thrombotic states.
Methods:
Patients with AF were enrolled, and the participants were divided into three groups based on the results of the echocardiogram: non-SEC, low-SEC and high-SEC group. Samples were collected and subjected to non-targeted metabolomics analysis. The analytical process included data quality control, metabolite difference analysis, component analysis, Kegg cluster analysis, etc. RESULTS: Our metabolic phenotype revealed a clear differential metabolic pattern between the SEC and non-SEC. Specifically, we identified 35 and 142 significantly differential metabolites in venous and atrial plasma, respectively, suggesting that SEC may be involved in pervasive metabolic dysregulation and that the degree of metabolic dysregulation in atrial plasma is more severe than that in venous blood.
Conclusion:
Patients with SEC have a significantly different metabolic pattern compared to those without SEC. Our work promoted the understanding of mechanism of the occurrence and development of SEC, facilitated the screening of the target metabolites for its therapeutic intervention, and provided evidence for the prevention and treatment of SEC or thrombosis in AF. Our work also provided new directions for subsequent research in related fields. In conclusion, our study not only provides a theoretical basis for understanding the occurrence and development of SEC in AF, but also provides recommendations for the daily diet of AF patients with SEC, such as a balanced intake of essential amino acids, avoiding excessive intake of benzoic acid, and intake of appropriate inositol.
Clinical Trial Number:
Not applicable.
More Related Videos
09:17High-Resolution Endocardial and Epicardial Optical Mapping in a Sheep Model of Stretch-Induced Atrial Fibrillation
Published on: July 29, 2011
05:30Author Spotlight: Advancing the Analysis of Plasma Extracellular Vesicle Proteome for Cardiovascular Biomarker Studies
Published on: January 31, 2025
